EDP Sciences logo
Subscriber Authentication Point
rechercher
Menu
Accueil Tous les numéros Volume 217 / Numéro 3-4 (2023) Biologie Aujourd’hui, 217 3-4 (2023) 133-144 References
Free Access
Issue
Biologie Aujourd’hui
Volume 217, Number 3-4, 2023
Page(s) 133 - 144
DOI https://doi.org/10.1051/jbio/2023026
Published online 29 novembre 2023
  • Abdallah, C.G. (2017). What’s the buzz about hydroxynorketamine? Is it the history, the story, the debate, or the promise? Biol Psychiatry, 81, e61-e63. [CrossRef] [PubMed] [Google Scholar]
  • Abdallah, C.G., De Feyter, H.M., Averill, L.A., Jiang, L., Averill, C.L., Chowdhury, G.M.I., Purohit, P., de Graaf, R.A., Esterlis, I., Juchem, C., Pittman, B.P., Krystal, J.H., Rothman, D.L., Sanacora, G., Mason, G.F. (2018). The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. Neuropsychopharmacology, 43, 2154-2160. [CrossRef] [PubMed] [Google Scholar]
  • Abdallah, C.G., Averill, L.A., Gueorguieva, R., Goktas, S., Purohit, P., Ranganathan, M., Sherif, M., Ahn, K.H., D’Souza, D.C., Formica, R., Southwick, S.M., Duman, R.S., Sanacora, G., Krystal, J.H. (2020). Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. Neuropsychopharmacology, 45, 990-997. [CrossRef] [PubMed] [Google Scholar]
  • Ago, Y., Tanabe, W., Higuchi, M., Tsukada, S., Tanaka, T., Yamaguchi, T., Igarashi, H., Yokoyama, R., Seiriki, K., Kasai, A., Nakazawa, T., Nakagawa, S., Hashimoto, K., Hashimoto, H. (2019). (R)-ketamine induces a greater increase in prefrontal 5-HT release than (S)-ketamine and ketamine metabolites via an AMPA receptor-independent mechanism. Int J Neuropsychopharmacol, 22, 665-674. [CrossRef] [PubMed] [Google Scholar]
  • Amargós-Bosch, M., López-Gil, X., Artigas, F., Adell, A. (2006). Clozapine and olanzapine, but not haloperidol, suppress serotonin efflux in the medial prefrontal cortex elicited by phencyclidine and ketamine. Int J Neuropsychopharmacol, 9, 565-573. [CrossRef] [PubMed] [Google Scholar]
  • Autry, A.E., Adachi, M., Nosyreva, E., Na, E.S., Los, M.F., Cheng, P.F., Kavalali, E.T., Monteggia, L.M. (2011). NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature, 475, 91-95. [CrossRef] [PubMed] [Google Scholar]
  • Averill, L.A., Averill, C.L., Gueorguieva, R., Fouda, S., Sherif, M., Ahn, K.H., Ranganathan, M., D’Souza, D.C., Southwick, S.M., Sanacora, G., Duman, R.S., Krystal, J.H., Abdallah, C.G. (2022). mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression. J Affect Disord, 303, 91-97. [CrossRef] [PubMed] [Google Scholar]
  • Bahji, A., Vazquez, G.H., Zarate, C.A., Jr. (2021). Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. J Affect Disord, 278, 542-555. [CrossRef] [PubMed] [Google Scholar]
  • Barrett, W., Buxhoeveden, M., Dhillon, S. (2020). Ketamine: A versatile tool for anesthesia and analgesia. Curr Opin Anaesthesiol, 33, 633-638. [CrossRef] [PubMed] [Google Scholar]
  • Berman, R.M., Cappiello, A., Anand, A., Oren, D.A., Heninger, G.R., Charney, D.S., Krystal, J.H. (2000). Antidepressant effects of ketamine in depressed patients. Biol Psychiatry, 47, 351-354. [CrossRef] [PubMed] [Google Scholar]
  • Bessa, J.M., Ferreira, D., Melo, I., Marques, F., Cerqueira, J.J., Palha, J.A., Almeida, O.F., Sousa, N. (2009). The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling. Mol Psychiatry, 14, 764-773. [Google Scholar]
  • Boldrini, M., Hen, R., Underwood, M.D., Rosoklija, G.B., Dwork, A.J., Mann, J.J., Arango, V. (2012). Hippocampal angiogenesis and progenitor cell proliferation are increased with antidepressant use in major depression. Biol Psychiatry, 72, 562-571. [CrossRef] [PubMed] [Google Scholar]
  • Boldrini, M., Fulmore, C.A., Tartt, A.N., Simeon, L.R., Pavlova, I., Poposka, V., Rosoklija, G.B., Stankov, A., Arango, V., Dwork, A.J., Hen, R., Mann, J.J. (2018). Human hippocampal neurogenesis persists throughout aging. Cell Stem Cell, 22, 589-599.e5. [CrossRef] [PubMed] [Google Scholar]
  • Bonaventura, J., Lam, S., Carlton, M., Boehm, M.A., Gomez, J.L., Solís, O., Sánchez-Soto, M., Morris, P.J., Fredriksson, I., Thomas, C.J., Sibley, D.R., Shaham, Y., Zarate, C.A., Michaelides, M. (2021). Pharmacological and behavioral divergence of ketamine enantiomers: Implications for abuse liability. Mol Psychiatry, 26, 6704-6722. [CrossRef] [PubMed] [Google Scholar]
  • Bonaventura, J., Lam, S., Carlton, M., Boehm, M., Gomez, J.L., Solís, O., Sánchez-Soto, M., Morris, P.J., Fredriksson, I., Thomas, C.J., Sibley, D.R., Shaham, Y., Zarate, C.A., Jr., Michaelides, M. (2022). Time will tell. Reply to “Comments to pharmacological and behavioral divergence of ketamine enantiomers by Jordi Bonaventura et al.” by Chen et al. Mol Psychiatry, 27, 1863-1865. [CrossRef] [PubMed] [Google Scholar]
  • Bottemanne, H., Bonnard, E., Claret, A., Petit, A.C., Gaillard, R., Fossati, P. (2020). Ketamine and monoamine oxidase inhibitor combination: Utility, safety, efficacy? J Clin Psychopharmacol, 40, 636-638. [CrossRef] [PubMed] [Google Scholar]
  • Bottemanne, H., Claret, A., Fossati, P. (2021). Ketamine, psilocybin, and rapid acting antidepressant: New promise for psychiatry? Encephale, 47, 171-178. [CrossRef] [PubMed] [Google Scholar]
  • Canuso, C.M., Singh, J.B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., Drevets, W.C. (2018). Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: Results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry, 175, 620-630. [CrossRef] [PubMed] [Google Scholar]
  • Carreno, F.R., Donegan, J.J., Boley, A.M., Shah, A., DeGuzman, M., Frazer, A., Lodge, D.J. (2016). Activation of a ventral hippocampus-medial prefrontal cortex pathway is both necessary and sufficient for an antidepressant response to ketamine. Mol Psychiatry, 21, 1298-1308. [CrossRef] [PubMed] [Google Scholar]
  • Celada, P., Lladó-Pelfort, L., Santana, N., Kargieman, L., Troyano-Rodriguez, E., Riga, M.S., Artigas, F. (2013). Disruption of thalamocortical activity in schizophrenia models: Relevance to antipsychotic drug action. Int J Neuropsychopharmacol, 16, 2145-2163. [CrossRef] [PubMed] [Google Scholar]
  • Chang, L., Zhang, K., Pu, Y., Qu, Y., Wang, S.M., Xiong, Z., Ren, Q., Dong, C., Fujita, Y., Hashimoto, K. (2019). Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine. Pharmacol Biochem Behav, 181, 53-59. [CrossRef] [PubMed] [Google Scholar]
  • Chazan, S., Ekstein, M.P., Marouani, N., Weinbroum, A.A. (2008). Ketamine for acute and subacute pain in opioid-tolerant patients. J Opioid, 4, 173-180. [Google Scholar]
  • Chowdhury, G.M., Behar, K.L., Cho, W., Thomas, M.A., Rothman, D.L., Sanacora, G. (2012). 1H-[13C]-nuclear magnetic resonance spectroscopy measures of ketamine’s effect on amino acid neurotransmitter metabolism. Biol Psychiatry, 71, 1022-1025. [CrossRef] [PubMed] [Google Scholar]
  • Chowdhury, G.M., Zhang, J., Thomas, M., Banasr, M., Ma, X., Pittman, B., Bristow, L., Schaeffer, E., Duman, R.S., Rothman, D.L., Behar, K.L., Sanacora, G. (2017). Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects. Mol Psychiatry, 22, 120-126. [CrossRef] [PubMed] [Google Scholar]
  • Corriger, A., Pickering, G. (2019). Ketamine and depression: A narrative review. Drug Des Devel Ther, 13, 3051-3067. [CrossRef] [Google Scholar]
  • Daly, E.J., Singh, J.B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R.C., Thase, M.E., Winokur, A., Van Nueten, L., Manji, H., Drevets, W.C. (2018). Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry, 75, 139-148. [CrossRef] [MathSciNet] [PubMed] [Google Scholar]
  • David, D.J., Samuels, B.A., Rainer, Q., Wang, J.W., Marsteller, D., Mendez, I., Drew, M., Craig, D.A., Guiard, B.P., Guilloux, J.P., Artymyshyn, R.P., Gardier, A.M., Gerald, C., Antonijevic, I.A., Leonardo, E.D., Hen, R. (2009). Neurogenesis-dependent and −independent effects of fluoxetine in an animal model of anxiety/depression. Neuron, 62, 479-493. [CrossRef] [PubMed] [Google Scholar]
  • Domino, E.F. (2010). Taming the ketamine tiger. 1965. Anesthesiology, 113, 678-684. [CrossRef] [PubMed] [Google Scholar]
  • Duman, R.S., Li, N., Liu, R.J., Duric, V., Aghajanian, G. (2012). Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology, 62, 35-41. [CrossRef] [PubMed] [Google Scholar]
  • Duman, R.S., Sanacora, G., Krystal, J.H. (2019). Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments. Neuron, 102, 75-90. [CrossRef] [PubMed] [Google Scholar]
  • Ebert, B., Mikkelsen, S., Thorkildsen, C., Borgbjerg, F.M. (1997). Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol, 333, 99-104. [CrossRef] [PubMed] [Google Scholar]
  • Eriksson, P.S., Perfilieva, E., Björk-Eriksson, T., Alborn, A.-M., Nordborg, C., Peterson, D.A., Gage, F.H. (1998). Neurogenesis in the adult human hippocampus. Nat Med, 4, 1313-1317. [CrossRef] [PubMed] [Google Scholar]
  • Erritzoe, D., Godlewska, B.R., Rizzo, G., Searle, G.E., Agnorelli, C., Lewis, Y., Ashok, A.H., Colasanti, A., Boura, I., Farrell, C., Parfitt, H., Howes, O., Passchier, J., Gunn, R.N., Politis, M., Nutt, D.J., Cowen, P.J., Knudsen, G.M., Rabiner, E.A. (2022). Brain serotonin release is reduced in patients with depression: A [(11)C]Cimbi-36 positron emission tomography study with a d-Amphetamine challenge. Biol Psychiatry, 93, 1089-1098. [Google Scholar]
  • Farmer, C.A., Gilbert, J.R., Moaddel, R., George, J., Adeojo, L., Lovett, J., Nugent, A.C., Kadriu, B., Yuan, P., Gould, T.D., Park, L.T., Zarate, C.A. (2020). Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression. Neuropsychopharmacology, 45, 1398-1404. [CrossRef] [PubMed] [Google Scholar]
  • Fuchs, T., Jefferson, S.J., Hooper, A., Yee, P.H., Maguire, J., Luscher, B. (2017). Disinhibition of somatostatin-positive GABAergic interneurons results in an anxiolytic and antidepressant-like brain state. Mol Psychiatry, 22, 920-930. [CrossRef] [PubMed] [Google Scholar]
  • Gaynes, B.N., Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Spencer, D., Fava, M. (2008). The STAR*D study: Treating depression in the real world. Cleve Clin J Med, 75, 57-66. [CrossRef] [PubMed] [Google Scholar]
  • Gerhard, D.M., Pothula, S., Liu, R.J., Wu, M., Li, X.Y., Girgenti, M.J., Taylor, S.R., Duman, C.H., Delpire, E., Picciotto, M., Wohleb, E.S., Duman, R.S. (2020). GABA interneurons are the cellular trigger for ketamine’s rapid antidepressant actions. J Clin Invest, 130, 1336-1349. [CrossRef] [PubMed] [Google Scholar]
  • Gideons, E.S., Kavalali, E.T., Monteggia, L.M. (2014). Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. Proc Natl Acad Sci USA, 111, 8649-8654. [CrossRef] [PubMed] [Google Scholar]
  • Gould, T.D., Zarate, C.A., Jr., Thompson, S.M. (2019). Molecular pharmacology and neurobiology of rapid-acting antidepressants. Annu Rev Pharmacol Toxicol, 59, 213-236. [CrossRef] [PubMed] [Google Scholar]
  • Hare, B.D., Duman, R.S. (2020). Prefrontal cortex circuits in depression and anxiety: Contribution of discrete neuronal populations and target regions. Mol Psychiatry, 25, 2742-2758. [CrossRef] [PubMed] [Google Scholar]
  • Hare, B.D., Ghosal, S., Duman, R.S. (2017). Rapid acting antidepressants in chronic stress models: Molecular and cellular mechanisms. Chronic Stress (Thousand Oaks), 1, https://doi.org/10.1177/2470547017697317. [PubMed] [Google Scholar]
  • Hare, B.D., Pothula, S., DiLeone, R.J., Duman, R.S. (2020). Ketamine increases vmPFC activity: Effects of (R)- and (S)-stereoisomers and (2R,6R)-hydroxynorketamine metabolite. Neuropharmacology, 166, 107947. [CrossRef] [PubMed] [Google Scholar]
  • Hasler, G., Fromm, S., Carlson, P.J., Luckenbaugh, D.A., Waldeck, T., Geraci, M., Roiser, J.P., Neumeister, A., Meyers, N., Charney, D.S., Drevets, W.C. (2008). Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. Arch Gen Psychiatry, 65, 521-531. [CrossRef] [MathSciNet] [PubMed] [Google Scholar]
  • Helm, M.S., Dankovich, T.M., Mandad, S., Rammner, B., Jähne, S., Salimi, V., Koerbs, C., Leibrandt, R., Urlaub, H., Schikorski, T., Rizzoli, S.O. (2021). A large-scale nanoscopy and biochemistry analysis of postsynaptic dendritic spines. Nat Neurosci, 24, 1151-1162. [CrossRef] [PubMed] [Google Scholar]
  • Highland, J.N., Morris, P.J., Konrath, K.M., Riggs, L.M., Hagen, N.R., Zanos, P., Powels, C.F., Moaddel, R., Thomas, C.J., Wang, A.Q., Gould, T.D. (2022). Hydroxynorketamine pharmacokinetics and antidepressant behavioral effects of (2,6)- and (5R)-Methyl-(2R,6R)-hydroxynorketamines. ACS Chem Neurosci, 13, 510-523. [CrossRef] [PubMed] [Google Scholar]
  • Jawad, M.Y., Di Vincenzo, J.D., Ceban, F., Jaberi, S., Lui, L.M.W., Gillissie, E.S., Alnafeesi, Y., Rosenblat, J.D., McIntyre, R.S. (2022). The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: A systematic review and meta-analysis. Expert Opin Drug Saf, 21, 841-852. [CrossRef] [PubMed] [Google Scholar]
  • Jelen, L.A., Young, A.H., Stone, J.M. (2021). Ketamine: A tale of two enantiomers. J Psychopharmacol, 35, 109-123. [CrossRef] [PubMed] [Google Scholar]
  • Kasai, H., Matsuzaki, M., Noguchi, J., Yasumatsu, N., Nakahara, H. (2003). Structure-stability-function relationships of dendritic spines. Trends Neurosci, 26, 360-368. [CrossRef] [PubMed] [Google Scholar]
  • Kempermann, G., Kuhn, H.G., Gage, F.H. (1998). Experience-induced neurogenesis in the senescent dentate gyrus. J Neurosci, 18, 3206-3212. [CrossRef] [PubMed] [Google Scholar]
  • Kim, M.J., Dunah, A.W., Wang, Y.T., Sheng, M. (2005). Differential roles of NR2A- and NR2B-containing NMDA receptors in Ras-ERK signaling and AMPA receptor trafficking. Neuron, 46, 745-760. [CrossRef] [PubMed] [Google Scholar]
  • Kim, B., Kim, C.Y., Hong, J.P., Kim, S.Y., Lee, C., Joo, Y.H. (2008). Brain-derived neurotrophic factor val/met polymorphism and bipolar disorder. Neuropsychobiology, 58, 97-103. [Google Scholar]
  • Kohtala, S. (2021). Ketamine-50 years in use: From anesthesia to rapid antidepressant effects and neurobiological mechanisms. Pharmacol Rep, 73, 323-345. [CrossRef] [PubMed] [Google Scholar]
  • Krystal, J.H., Karper, L.P., Seibyl, J.P., Freeman, G.K., Delaney, R., Bremner, J.D., Heninger, G.R., Bowers, M.B., Jr., Charney, D.S. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry, 51, 199-214. [CrossRef] [PubMed] [Google Scholar]
  • Lapidus, K.A., Levitch, C.F., Perez, A.M., Brallier, J.W., Parides, M.K., Soleimani, L., Feder, A., Iosifescu, D.V., Charney, D.S., Murrough, J.W. (2014). A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry, 76, 970-976. [CrossRef] [PubMed] [Google Scholar]
  • Leal, G.C., Souza-Marques, B., Mello, R.P., Bandeira, I.D., Caliman-Fontes, A.T., Carneiro, B.A., Faria-Guimarães, D., Guerreiro-Costa, L.N.F., Jesus-Nunes, A.P., Silva, S.S., Lins-Silva, D.H., Fontes, M.A., Alves-Pereira, R., Cordeiro, V., Rugieri-Pacheco, S., Santos-Lima, C., Correia-Melo, F.S., Vieira, F., Sanacora, G., Lacerda, A.L.T., Quarantini, L.C. (2023). Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study. J Affect Disord, 330, 7-15. [CrossRef] [PubMed] [Google Scholar]
  • Li, N., Lee, B., Liu, R.J., Banasr, M., Dwyer, J.M., Iwata, M., Li, X.Y., Aghajanian, G., Duman, R.S. (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science, 329, 959-964. [CrossRef] [PubMed] [Google Scholar]
  • Li, N., Liu, R.J., Dwyer, J.M., Banasr, M., Lee, B., Son, H., Li, X.Y., Aghajanian, G., Duman, R.S. (2011). Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry, 69, 754-761. [CrossRef] [MathSciNet] [Google Scholar]
  • Lin, P.-Y., Ma, Z.Z., Mahgoub, M., Kavalali, E.T., Monteggia, L.M. (2021). A synaptic locus for TrkB signaling underlying ketamine rapid antidepressant action. Cell Rep, 36, 109513. [CrossRef] [PubMed] [Google Scholar]
  • Liu, R.J., Lee, F.S., Li, X.Y., Bambico, F., Duman, R.S., Aghajanian, G.K. (2012). Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry, 71, 996-1005. [CrossRef] [PubMed] [Google Scholar]
  • Liu, R.J., Fuchikami, M., Dwyer, J.M., Lepack, A.E., Duman, R.S., Aghajanian, G.K. (2013). GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology, 38, 2268-2277. [CrossRef] [PubMed] [Google Scholar]
  • López-Gil, X., Babot, Z., Amargós-Bosch, M., Suñol, C., Artigas, F., Adell, A. (2007). Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology, 32, 2087-2097. [CrossRef] [PubMed] [Google Scholar]
  • Lord, B., Wintmolders, C., Langlois, X., Nguyen, L., Lovenberg, T., Bonaventure, P. (2013). Comparison of the ex vivo receptor occupancy profile of ketamine to several NMDA receptor antagonists in mouse hippocampus. Eur J Pharmacol, 715, 21-25. [CrossRef] [PubMed] [Google Scholar]
  • Lorrain, D.S., Baccei, C.S., Bristow, L.J., Anderson, J.J., Varney, M.A. (2003). Effects of ketamine and n-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: Modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience, 117, 697-706. [CrossRef] [PubMed] [Google Scholar]
  • Lumsden, E.W., Troppoli, T.A., Myers, S.J., Zanos, P., Aracava, Y., Kehr, J., Lovett, J., Kim, S., Wang, F.H., Schmidt, S., Jenne, C.E., Yuan, P., Morris, P.J., Thomas, C.J., Zarate, C.A., Jr., Moaddel, R., Traynelis, S.F., Pereira, E.F.R., Thompson, S.M., Albuquerque, E.X., Gould, T.D. (2019). Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function. Proc Natl Acad Sci USA, 116, 5160-5169. [CrossRef] [PubMed] [Google Scholar]
  • Maeng, S., Zarate, C.A., Jr., Du, J., Schloesser, R.J., McCammon, J., Chen, G., Manji, H.K. (2008). Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry, 63, 349-352. [CrossRef] [PubMed] [Google Scholar]
  • Marcantoni, W.S., Akoumba, B.S., Wassef, M., Mayrand, J., Lai, H., Richard-Devantoy, S., Beauchamp, S. (2020). A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009–January 2019. J Affect Disord, 277, 831-841. [CrossRef] [PubMed] [Google Scholar]
  • Marland, S., Ellerton, J., Andolfatto, G., Strapazzon, G., Thomassen, O., Brandner, B., Weatherall, A., Paal, P. (2013). Ketamine: Use in anesthesia. CNS Neurosci Ther, 19, 381-389. [CrossRef] [PubMed] [Google Scholar]
  • Matsuzaki, M., Ellis-Davies, G.C., Nemoto, T., Miyashita, Y., Iino, M., Kasai, H. (2001). Dendritic spine geometry is critical for AMPA receptor expression in hippocampal CA1 pyramidal neurons. Nat Neurosci, 4, 1086-1092. [CrossRef] [PubMed] [Google Scholar]
  • Meiering, M.S., Weigner, D., Gärtner, M., Schäfer, T., Grimm, S. (2022). Does route of administration affect antidepressant efficacy of ketamine? A meta-analysis of double-blind randomized controlled trials comparing intravenous and intranasal administration. J Psychiatr Res, 156, 639-646. [CrossRef] [PubMed] [Google Scholar]
  • Miller, O.H., Moran, J.T., Hall, B.J. (2016). Two cellular hypotheses explaining the initiation of ketamine’s antidepressant actions: Direct inhibition and disinhibition. Neuropharmacology, 100, 17-26. [CrossRef] [PubMed] [Google Scholar]
  • Mitchell, A.J., Chan, M., Bhatti, H., Halton, M., Grassi, L., Johansen, C., Meader, N. (2011). Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: A meta-analysis of 94 interview-based studies. Lancet Oncol, 12, 160-174. [CrossRef] [PubMed] [Google Scholar]
  • Moda-Sava, R.N., Murdock, M.H., Parekh, P.K., Fetcho, R.N., Huang, B.S., Huynh, T.N., Witztum, J., Shaver, D.C., Rosenthal, D.L., Alway, E.J., Lopez, K., Meng, Y., Nellissen, L., Grosenick, L., Milner, T.A., Deisseroth, K., Bito, H., Kasai, H., Liston, C. (2019). Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science, 364(6436), eaat8078. [CrossRef] [PubMed] [Google Scholar]
  • Moghaddam, B., Adams, B., Verma, A., Daly, D. (1997). Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci, 17, 2921-2927. [CrossRef] [PubMed] [Google Scholar]
  • Motov, S., Rockoff, B., Cohen, V., Pushkar, I., Likourezos, A., McKay, C., Soleyman-Zomalan, E., Homel, P., Terentiev, V., Fromm, C. (2015). Intravenous subdissociative-dose ketamine versus morphine for analgesia in the Emergency Department: A randomized controlled trial. Ann Emerg Med, 66, 222-229. [CrossRef] [PubMed] [Google Scholar]
  • Murray, F., Kennedy, J., Hutson, P.H., Elliot, J., Huscroft, I., Mohnen, K., Russell, M.G., Grimwood, S. (2000). Modulation of [3H]MK-801 binding to NMDA receptors in vivo and in vitro. Eur J Pharmacol, 397, 263-270. [CrossRef] [PubMed] [Google Scholar]
  • Murrough, J.W., Iosifescu, D.V., Chang, L.C., Al Jurdi, R.K., Green, C.E., Perez, A.M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., Charney, D.S., Mathew, S.J. (2013). Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. Am J Psychiatry, 170, 1134-1142. [CrossRef] [PubMed] [Google Scholar]
  • Naegelin, Y., Dingsdale, H., Säuberli, K., Schädelin, S., Kappos, L., Barde, Y.A. (2018). Measuring and validating the levels of brain-derived neurotrophic factor in human serum. eNeuro, 5(2), e0419-17. [Google Scholar]
  • Neumeister, A., Nugent, A.C., Waldeck, T., Geraci, M., Schwarz, M., Bonne, O., Bain, E.E., Luckenbaugh, D.A., Herscovitch, P., Charney, D.S., Drevets, W.C. (2004). Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch Gen Psychiatry, 61, 765-773. [CrossRef] [PubMed] [Google Scholar]
  • Nguyen, T.M.L., Defaix, C., Mendez-David, I., Tritschler, L., Etting, I., Alvarez, J.C., Choucha, W., Colle, R., Corruble, E., David, D.J., Gardier, A.M. (2023). Intranasal (R,S)-ketamine delivery induces sustained antidepressant effects associated with changes in cortical balance of excitatory/inhibitory synaptic activity. Neuropharmacology, 225, 109357. [CrossRef] [PubMed] [Google Scholar]
  • Nibuya, M., Morinobu, S., Duman, R.S. (1995). Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci, 15, 7539-7547. [CrossRef] [PubMed] [Google Scholar]
  • Niciu, M.J., Kelmendi, B., Sanacora, G. (2012). Overview of glutamatergic neurotransmission in the nervous system. Pharmacol Biochem Behav, 100, 656-664. [CrossRef] [PubMed] [Google Scholar]
  • Parekh, P.K., Johnson, S.B., Liston, C. (2022). Synaptic mechanisms regulating mood state transitions in depression. Annu Rev Neurosci, 45, 581-601. [CrossRef] [PubMed] [Google Scholar]
  • Pham, T.H., Gardier, A.M. (2019). Fast-acting antidepressant activity of ketamine: Highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies. Pharmacol Ther, 199, 58-90. [CrossRef] [PubMed] [Google Scholar]
  • Pham, T.H., Mendez-David, I., Defaix, C., Guiard, B.P., Tritschler, L., David, D.J., Gardier, A.M. (2017). Ketamine treatment involves medial prefrontal cortex serotonin to induce a rapid antidepressant-like activity in BALB/cJ mice. Neuropharmacology, 112, 198-209. [CrossRef] [PubMed] [Google Scholar]
  • Pham, T.H., Defaix, C., Xu, X., Deng, S.X., Fabresse, N., Alvarez, J.C., Landry, D.W., Brachman, R.A., Denny, C.A., Gardier, A.M. (2018). Common neurotransmission recruited in (R,S)-ketamine and (2R,6R)-hydroxynorketamine-induced sustained antidepressant-like effects. Biol Psychiatry, 84, e3-e6. [CrossRef] [PubMed] [Google Scholar]
  • Pham, T.H., Defaix, C., Nguyen, T.M.L., Mendez-David, I., Tritschler, L., David, D.J., Gardier, A.M. (2020). Cortical and raphe GABAA, AMPA receptors and glial GLT-1 glutamate transporter contribute to the sustained antidepressant activity of ketamine. Pharmacol Biochem Behav, 192, 172913. [CrossRef] [PubMed] [Google Scholar]
  • Pothula, S., Kato, T., Liu, R.-J., Wu, M., Gerhard, D., Shinohara, R., Sliby, A.-N., Chowdhury, G.M.I., Behar, K.L., Sanacora, G., Banerjee, P., Duman, R.S. (2021). Cell-type specific modulation of NMDA receptors triggers antidepressant actions. Mol Psychiatry, 26, 5097-5111. [CrossRef] [PubMed] [Google Scholar]
  • Pozzi, L., Dorocic, I.P., Wang, X., Carlén, M., Meletis, K. (2014). Mice lacking NMDA receptors in parvalbumin neurons display normal depression-related behavior and response to antidepressant action of NMDAR antagonists. PLoS One, 9, e83879. [CrossRef] [PubMed] [Google Scholar]
  • Prins, J., Olivier, B., Korte, S.M. (2011). Triple reuptake inhibitors for treating subtypes of major depressive disorder: The monoamine hypothesis revisited. Expert Opin Investig Drugs, 20, 1107-1130. [CrossRef] [PubMed] [Google Scholar]
  • Razoux, F., Garcia, R., Léna, I. (2007). Ketamine, at a dose that disrupts motor behavior and latent inhibition, enhances prefrontal cortex synaptic efficacy and glutamate release in the nucleus accumbens. Neuropsychopharmacology, 32, 719-727. [CrossRef] [PubMed] [Google Scholar]
  • Ruhé, H.G., Mason, N.S., Schene, A.H. (2007). Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: A meta-analysis of monoamine depletion studies. Mol Psychiatry, 12, 331-359. [Google Scholar]
  • Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., Belzung, C., Hen, R. (2003). Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science, 301, 805-809. [CrossRef] [PubMed] [Google Scholar]
  • Shim, I. (2022). Distinct functions of S-ketamine and R-ketamine in mediating biobehavioral processes of drug dependency: Comments on Bonaventura et al. Mol Psychiatry. https://doi.org/10.1038/s41380-022-01629-0. [PubMed] [Google Scholar]
  • Tartt, A.N., Mariani, M.B., Hen, R., Mann, J.J., Boldrini, M. (2022). Dysregulation of adult hippocampal neuroplasticity in major depression: Pathogenesis and therapeutic implications. Mol Psychiatry, 27, 2689-2699. [CrossRef] [PubMed] [Google Scholar]
  • Tizabi, Y., Bhatti, B.H., Manaye, K.F., Das, J.R., Akinfiresoye, L. (2012) Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar/Kyoto rats. Neuroscience, 213, 72-80. [CrossRef] [PubMed] [Google Scholar]
  • Traynelis, S.F., Wollmuth, L.P., McBain, C.J., Menniti, F.S., Vance, K.M., Ogden, K.K., Hansen, K.B., Yuan, H., Myers, S.J., Dingledine, R. (2010). Glutamate receptor ion channels: Structure, regulation, and function. Pharmacol Rev, 62, 405-496. [CrossRef] [PubMed] [Google Scholar]
  • White, P.F., Schüttler, J., Shafer, A., Stanski, D.R., Horai, Y., Trevor, A.J. (1985). Comparative pharmacology of the ketamine isomers. Studies in volunteers. Br J Anaesth, 57, 197-203. [CrossRef] [PubMed] [Google Scholar]
  • Wu, H., Savalia, N.K., Kwan, A.C. (2021). Ketamine for a boost of neural plasticity: How, but also when? Biol Psychiatry, 89, 1030-1032. [CrossRef] [PubMed] [Google Scholar]
  • Yang, C., Ren, Q., Qu, Y., Zhang, J.C., Ma, M., Dong, C., Hashimoto, K. (2018). Mechanistic target of rapamycin-independent antidepressant effects of (R)-ketamine in a social defeat stress model. Biol Psychiatry, 83, 18-28. [CrossRef] [PubMed] [Google Scholar]
  • Zanos, P., Moaddel, R., Morris, P.J., Georgiou, P., Fischell, J., Elmer, G.I., Alkondon, M., Yuan, P., Pribut, H.J., Singh, N.S., Dossou, K.S., Fang, Y., Huang, X.P., Mayo, C.L., Wainer, I.W., Albuquerque, E.X., Thompson, S.M., Thomas, C.J., Zarate, C.A., Jr., Gould, T.D. (2016). NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature, 533, 481-486. [CrossRef] [PubMed] [Google Scholar]
  • Zanos, P., Highland, J.N., Stewart, B.W., Georgiou, P., Jenne, C.E., Lovett, J., Morris, P.J., Thomas, C.J., Moaddel, R., Zarate, C.A., Gould, T.D. (2019). (2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions. Proc Natl Acad Sci USA, 116, 6441-6450. [CrossRef] [PubMed] [Google Scholar]
  • Zarate, C.A., Jr., Singh, J.B., Carlson, P.J., Brutsche, N.E., Ameli, R., Luckenbaugh, D.A., Charney, D.S., Manji, H.K. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry, 63, 856-864. [CrossRef] [PubMed] [Google Scholar]
  • Zheng, W., Zhou, Y.L., Liu, W.J., Wang, C.Y., Zhan, Y.N., Lan, X.F., Zhang, B., Ning, Y.P. (2020). A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression. J Affect Disord, 275, 38-43. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.